Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?

Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and antiretroviral-free remission. BnAbs can neutralize HIV-1 and target infected cells for elimination. Concerns about HIV-1 re...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-07, Vol.12, p.710044-710044
Main Authors: Hsu, Denise C, Mellors, John W, Vasan, Sandhya
Format: Article
Language:English
Subjects:
Anti-Retroviral Agents - therapeutic use
Broadly Neutralizing Antibodies - immunology
broadly neutralizing HIV-1 antibody
Clinical Trials as Topic
HIV Antibodies - immunology
HIV cure
HIV immunotherapy
HIV Infections - therapy
HIV Infections - virology
HIV remission
HIV therapeutics
Humans
Immunology
Vaccination
Virus Replication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and antiretroviral-free remission. BnAbs can neutralize HIV-1 and target infected cells for elimination. Concerns about HIV-1 resistance to single bnAbs have led to studies of bnAb combinations with non-overlapping resistance profiles. This review focuses on the potential for bnAbs to induce HIV-1 remission, either alone or in combination with latency reversing agents, therapeutic vaccines or other novel therapeutics. Key topics include preliminary activity of bnAbs in preclinical models and in human studies of HIV-1 remission, clinical trial designs, and antibody design strategies to optimize pharmacokinetics, coverage of rebound-competent virus, and enhancement of cellular immune functions.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.710044